AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04038970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat bread
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT05085925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral mindfulness intervention
Description: The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5
Study NCT05085925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral mindfulness intervention after 3-month wait list
Description: Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
Study NCT04636489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highland barley β-glucan dietary supplement
Description: 100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks
Study NCT04636489 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controls
Description: Placebo with a similar appearance and taste to highland barley β-glucan supplement
Study NCT01534026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Current dose
Study NCT01534026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: withdrawal of aspirin
Description: Stopping current dose of aspirin
Study NCT04063774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dengue calculator
Description: Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device
Study NCT04309916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan 50mg tablet
Study NCT04309916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40mg tablet
Study NCT02498834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video and Question Prompt List
Description: Educational Video and Question Prompt List
Study NCT02317926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Study NCT02317926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Plus Liothyronine
Study NCT02317926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desiccated Thyroid Extract
Study NCT02650050 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Micropulsed laser photocoagulation
Description: Micropulsed laser photocoagulation after 3 anti-VEGF injections
Study NCT02650050 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Micropulsed laser photocoagulation
Description: Micropulsed laser photocoagulation after 3 anti-VEGF injections
Study NCT00772590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Tablets, 400mg, twice daily
Study NCT00772590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper-immune Bovine Colostrum
Description: Tablet, 1800mg, twice daily
Study NCT00772590 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: raltegravir placebo
Description: One tablet, twice daily
Study NCT00772590 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyper-immune Bovine Colostrum placebo
Description: Three tablets twice daily
Study NCT00772590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir and hyper-immune bovine colostrum
Description: 400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
Study NCT01180348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulift
Description: Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
Study NCT01180348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
Study NCT01118364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving
Study NCT01118364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tobacco
Description: a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving
Study NCT00026143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given IV
Study NCT00026143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given SC
Study NCT00026143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00551252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate plus Gemcitabine
Description: Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
Study NCT04102579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study NCT04102579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active dosage form
Study NCT02572557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruFreeze Spray CryoTherapy
Description: TruFreeze Spray CryoTherapy using liquid nitrogen
Study NCT02572557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen
Description: TruFreeze Spray CryoTherapy using liquid nitrogen
Study NCT05899686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetanic Stimulus
Description: 5 second 100 Hz 70 mA tetanic stimulus will be applied to three different anatomical locations in each subject.
Study NCT03778879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX872-B
Description: CCX872-B concurrent with stereotactic body radiation therapy for pancreatic adenocarcinoma.
Study NCT04322123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Product
Description: Hydroxychloroquine 400 mg BID
Study NCT04322123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + azithromycin
Description: Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
Study NCT03322280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE combined with iodine-125 seeds implantation
Description: Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.
Study NCT03322280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Only conventional TACE with lipiodol and chemotherapy drugs was performed.
Study NCT02874495 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological tests
Description: Related to affective and cognitive dimensions of pain.
Study NCT02621957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
Study NCT02621957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
Study NCT02966756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral
Study NCT04284345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline Pd/Pa
Description: Use of a ≥6F guiding catheter and the Verrata pressure guidewire. Administration of intracoronary nitroglycerin.~Verrata normalisation and placement of the Verrata sensor ≥3 vessel-diameter beyond the stenosis.~Whole cycle resting Pd/Pa and resting iFR measurements.~Measurement of contrast FFR: record 5 baseline heart beats, injection of contrast media, 10 ml in the left coronary system, 8 ml in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Adenosine FFR: measurement: record 5 baseline heart beats, injection of intracoronary adenosine, 200 mcg in the left coronary system, 100 mcg in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Saline-induced Pd/Pa measurement: record 5 baseline heart beats, injection of saline using the ACIST system during 5 heart beats, measure minimal Pd/Pa under stable hyperaemia.~Perform pressure guidewire pullback and check for drift: drift ±0.02 is accepted, if ≥0.03, repeat measurement.
Study NCT00604032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atralin (tretinoin) Gel, 0.05%
Description: Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
Study NCT03740308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locally Made Zirconia Crowns
Description: Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
Study NCT03740308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZR Zirconia Crwons NuSmile ® Crowns
Description: Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
Study NCT03169218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.
Study NCT03169218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
Study NCT01048814 — intervention group
Intervention type: OTHER
Intervention: ChemoFx
Description: Chemoresponse Marker Assay
Study NCT01865955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound applied to the lumbar region to determine spinal needle placement.
Study NCT01865955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The spinal needle
Study NCT03182335 — intervention group
Intervention type: OTHER
Intervention: sedation awakening trial
Description: vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
Study NCT03155789 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar Fusion
Description: Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion
Study NCT02874495 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability.
Study NCT03419364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: 2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
Study NCT03846102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%
Study NCT03846102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0,9% for injection/infusion.
Study NCT03846102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 500 milligram tablet
Study NCT03846102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 500 milligram tablet
Study NCT03846102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine 1 mg/ml solution for infusion.
Study NCT03846102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Morphine 1 mg/ml solution for infusion.
Study NCT03846102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block with Levobupivacaine
Description: Ultrasound guided Fascia Iliaca Compartment Block with levobupivacaine placed in the emergency department by an emergency physician.
Study NCT03846102 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fascia Iliaca Compartment Block with placebo
Description: Ultrasound guided Fascia Iliaca Compartment Block with placebo placed in the emergency department by an emergency physician.
Study NCT01901107 — intervention group
Intervention type: DRUG
Intervention: Kiklin capsules
Description: oral
Study NCT01216930 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation
Study NCT02660814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: 1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
Study NCT02660814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.
Study NCT02660814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.
Study NCT02775955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX0041
Description: Active
Study NCT03450902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chinese herb & acupuncture
Description: Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
Study NCT03450902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herb & acupuncture
Description: Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
Study NCT03450902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chinese herb & sham acupuncture
Description: Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
Study NCT03450902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chinese herb & sham acupuncture
Description: Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
Study NCT03450902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herb & sham acupuncture
Description: Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
Study NCT03450902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo & acupuncture
Description: Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
Study NCT03450902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo & acupuncture
Description: Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
Study NCT03450902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & acupuncture
Description: Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
Study NCT03450902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo & sham acupuncture
Description: Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.